

3 Tips for Cologuard® Collection Kit Completion



Please review these points with your appropriate Cologuard patients to encourage timely test completion:

1

Reinforce the importance of screening on time

- Explain how screening on time is important because when detected in early stages, colorectal cancer (CRC) is more treatable^{1,2*†}

2

Set expectations

- Set a **2-week timeframe** to use the Cologuard collection kit
- Expect welcome outreach from the Exact Sciences Customer Care Center

3

Confirm collection and return process

- Store the Cologuard collection kit on the back of the toilet for easy use
- An acceptable stool sample should be no larger than the bottle of liquid in the kit and should not be provided if there is diarrhea or blood in the stool
- Patients should plan to collect their sample when they can get it back to UPS® on that same day or the next day
- **The Customer Care Center is available 24/7 to help patients complete their Cologuard collection kit at [1-844-870-8870](tel:1-844-870-8870)**

Patients should not provide a sample for Cologuard if they have diarrhea or if they have blood in their urine or stool (eg, from bleeding hemorrhoids, bleeding cuts or wounds on their hands, rectal bleeding, or menstruation). The risks related to using the Cologuard collection kit are low, with no serious adverse events reported among people in a clinical trial. Patients should be careful when opening and closing the lid to avoid the risk of hand strain.³



Explore Cologuard's comprehensive support, designed with your patients in mind

Visit CologuardHCP.com/Support

Indications and Important Risk Information

Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Cologuard is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months; have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn's disease; or have a family history of colorectal cancer, or certain hereditary syndromes.

Positive Cologuard results should be referred to diagnostic colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.

False positives and false negatives do occur. In a clinical study, 13% of patients without colorectal cancer or advanced adenomas received a positive result (false positive) and 8% of patients with cancer received a negative result (false negative). The clinical validation study was conducted in patients 50 years of age and older. Cologuard performance in patients ages 45 to 49 years was estimated by sub-group analysis of near-age groups.

Cologuard performance when used for repeat testing has not been evaluated or established. Rx only.

* Per American Joint Committee on Cancer's (AJCC) staging system: **Localized** = stage I, IIa, IIb. **Regional** = stage IIc and III. **Distant** = stage IV.⁴

† Based on people diagnosed with CRC in stage I, stage IIa, or stage IIb between 2011 and 2017.²

References: **1.** Cancer stat facts: colorectal cancer. National Cancer Institute. Accessed March 3, 2022. <https://seer.cancer.gov/statfacts/html/colorect.html>. **2.** Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72(1):7-33. doi:10.3322/caac.21708. **3.** Cologuard® Physician Brochure. Madison, WI: Exact Sciences Corporation. **4.** Survival rates for colorectal cancer. American Cancer Society. Accessed March 3, 2022. <https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html>.

EXACT SCIENCES CORPORATION | 5505 Endeavor Lane, Madison, WI 53719
ExactSciences.com | ExactLabs.com | 1-844-870-8870

Cologuard is a registered trademark of Exact Sciences Corporation. All other trademarks are the properties of their respective owners.

©2022 Exact Sciences Corporation. All rights reserved. M-US-Cologuard-01184-April 2022

